Author Correction: Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19

Nat Commun. 2025 Jan 21;16(1):891. doi: 10.1038/s41467-025-56341-8.

Yongzhi Lu^#^{1

2}, Qi Yang^#^{1

3}, Ting Ran^#¹, Guihua Zhang¹, Wenqi Li^{1

4}, Peiqi Zhou¹, Jielin Tang¹, Minxian Dai¹, Jinpeng Zhong¹, Hua Chen¹, Pan He¹, Anqi Zhou², Bao Xue¹, Jiayi Chen^{1

5}, Jiyun Zhang^{1

5}, Sidi Yang¹, Kunzhong Wu^{1

6}, Xinyu Wu¹, Miru Tang¹, Wei K Zhang¹, Deyin Guo^{1

3}, Xinwen Chen^{7

8}, Hongming Chen^{9

10}, Jinsai Shang^{11

12}

¹ Guangzhou National Laboratory, Guangzhou, 510005, China.
² School of Basic Medical Sciences, Guangzhou Laboratory, Guangzhou Medical University, Guangzhou, 511436, China.
³ State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, 511436, China.
⁴ College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.
⁵ School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
⁶ State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin, 300071, China.
⁷ Guangzhou National Laboratory, Guangzhou, 510005, China. [email protected].
⁸ State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, 511436, China. [email protected].
⁹ Guangzhou National Laboratory, Guangzhou, 510005, China. [email protected].
¹⁰ School of Basic Medical Sciences, Guangzhou Laboratory, Guangzhou Medical University, Guangzhou, 511436, China. [email protected].
¹¹ Guangzhou National Laboratory, Guangzhou, 510005, China. [email protected].
¹² School of Basic Medical Sciences, Guangzhou Laboratory, Guangzhou Medical University, Guangzhou, 511436, China. [email protected].

^# Contributed equally.

No abstract available

Publication types